Keyword: Imfinzi (durvalumab)
Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.
AstraZeneca and pro golfer Jason Day have teamed up on a campaign to encourage biomarker testing for lung cancer patients.
AZ's oncology portfolio jumped 59% in Q1 sales, and China turned up 28% growth. So CEO Pascal Soriot figured its time for some long-term planning.
Merck's Keytruda has leaped ahead of Bristol-Myers Squibb’s Opdivo and nabbed a green light in newly diagnosed non-small cell lung cancer.
AstraZeneca’s Imfinzi is working to grab sales in a rival-free sector of the lung cancer market, and England’s cost watchdogs just gave it a boost.
Just a week after Roche’s Tecentriq became the first FDA-approved I-O agent in breast cancer, the drug has clinched another first-in-class nod.
AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to its cancer drugs—and once again, China.
The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.
AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.
AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat.